• Neon Therapeutics

  Participated · Series B · Jan 2017

  Neon Therapeutics is a clinical-stage immuno-oncology company focused on directing the immune system toward neoantigens using a proprietary platform. Its lead product candidate, NEO-PV-01, is a personal neoantigen vaccine currently in a Phase 1b open-label trial for metastatic melanoma, non-small cell lung cancer, and bladder cancer. The company is also advancing NEO-PTC-01, a personal neoantigen T cell program, in preclinical development. Neon employs two development approaches: NEON/ONE for individualized neoantigens and NEON/SELECT targeting shared neoantigens across patient subsets and tumor types. Proceeds from its Series B crossover financing will support ongoing clinical and preclinical programs and continued development of the NEON/SELECT approach. The company positions itself as a leader in the neoantigen-targeted therapy field. Based in Cambridge, Mass., Neon Therapeutics develops therapeutics leveraging neoantigen biology to target cancer. Its lead program, NEO-PV-01, is a fully personalized neoantigen vaccine currently in a Phase 1b clinical trial. The company is also advancing NEO-PTC-01, a personalized adoptive T cell program in preclinical development, and a Shared Neoantigen Program. Neon operates a neoantigen-based product engine that enables multiple modalities, including next-generation vaccines and T cell therapies targeting both personalized and shared neoantigens. The company’s vaccine program builds upon research from the Broad Institute and Dana-Farber Cancer Institute. Neon recently completed a $70 million Series B financing to fund these programs. Neon Therapeutics is an immuno-oncology company building a neoantigen-based product engine to develop therapeutic vaccines and T cell modalities that target both personalized and shared neoantigens. Its lead program, NEO-PV-01, is a personalized neoantigen vaccine that builds on clinical research from the Broad Institute and Dana-Farber Cancer Institute and is already in multiple clinical trials. The company plans to initiate a company-sponsored clinical development program while supporting ongoing academic trials and to advance identification and delivery of the most effective neoantigens. Neon is also developing personalized T cell therapies that leverage its epitope-prediction and immune-monitoring capabilities. The founding team includes globally recognized experts in neoantigen biology and tumor immunology, such as James Allison, Eric Lander and Catherine Wu, who will continue to guide the company. Neon intends its therapies to be complementary to existing immunomodulatory approaches and to provide durable anti-tumor immune responses.

No current team members are available.